
AstraZeneca names controversial cancer scientist José Baselga to a top R&D post in major shakeup
Just days after Bahija Jallal announced her decision to leave her post at the top of AstraZeneca’s big biologics subsidiary MedImmune and take the helm at Immunocore, the pharma giant is shaking up its R&D leadership and bringing in a controversial new head of oncology R&D.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.